MAX
Company Analysis Universe Pharmaceuticals INC
1. Summary
Advantages
- Price (2.86 $) is less than fair price (4.08 $)
Disadvantages
- Dividends (0%) are below the sector average (0.55%).
- The stock's return over the last year (-39.15%) is lower than the sector average (33.9%).
- Current debt level 11.76% has increased over 5 years from 9.03%.
- The company's current efficiency (ROE=-19.18%) is lower than the sector average (ROE=102.4%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Universe Pharmaceuticals INC | Healthcare | Index | |
|---|---|---|---|
| 7 days | -1.7% | 0% | -1.2% |
| 90 days | -28.1% | 6% | -3.5% |
| 1 year | -39.1% | 33.9% | 17.8% |
UPC vs Sector: Universe Pharmaceuticals INC has significantly underperformed the "Healthcare" sector by -73.05% over the past year.
UPC vs Market: Universe Pharmaceuticals INC has significantly underperformed the market by -56.93% over the past year.
Stable price: UPC is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: UPC with weekly volatility of -0.75% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Below fair price: The current price (2.86 $) is lower than the fair price (4.08 $).
Price significantly below the fair price: The current price (2.86 $) is 42.7% lower than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (-0.002) is lower than that of the sector as a whole (29.98).
P/E vs Market: The company's P/E (-0.002) is higher than that of the market as a whole (-87.32).
5.3. P/BV
P/BV vs Sector: The company's P/BV (0.000383) is lower than that of the sector as a whole (249.13).
P/BV vs Market: The company's P/BV (0.000383) is lower than that of the market as a whole (82.22).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (0.000758) is lower than that of the sector as a whole (127.74).
P/S vs Market: The company's P/S indicator (0.000758) is lower than that of the market as a whole (115.2).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (2.92) is higher than that of the sector as a whole (-23.82).
EV/Ebitda vs Market: The company's EV/Ebitda (2.92) is higher than that of the market as a whole (-82.75).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -35.45% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-35.45%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (172.16%).
6.4. ROE
ROE vs Sector: The company's ROE (-19.18%) is lower than that of the sector as a whole (102.4%).
ROE vs Market: The company's ROE (-19.18%) is lower than that of the market as a whole (-6.94%).
6.6. ROA
ROA vs Sector: The company's ROA (-12.84%) is lower than that of the sector as a whole (-1.94%).
ROA vs Market: The company's ROA (-12.84%) is lower than that of the market as a whole (37.49%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0.7%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (9.35%).
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.55%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Based on sources: porti.ru
